PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29775223-0 2018 Curcumin down-regulates IL-17A mediated p53-fibrinolytic system in bleomycin induced acute lung injury in vivo. Curcumin 0-8 interleukin 17A Mus musculus 24-30 22402368-7 2012 Ex vivo and in vitro treatment with curcumin resulted in a dose-dependent decrease in the secretion of IFNgamma, IL-17, IL-12 and IL-23 in culture. Curcumin 36-44 interleukin 17A Mus musculus 113-118 28887914-10 2017 In vitro experiments showed that curcumin treatment directly decreased the Th1/Th2/Th17 cytokine production of IFN-gamma, IL-4, and IL-17A in CD4+ T cells. Curcumin 33-41 interleukin 17A Mus musculus 132-138 28273557-8 2017 Furthermore, expression of the Th17 cells related cytokine profiles (IL-17A and RORgammat) was dramatically decreased in curcumin-treated groups. Curcumin 121-129 interleukin 17A Mus musculus 69-75 23825622-8 2013 We inferred that curcumin was capable of impacting the IL-23/IL-17A axis by inhibiting IL-1beta/IL-6 and then indirectly down-regulating IL-17A/IL-22 production. Curcumin 17-25 interleukin 17A Mus musculus 61-67 23825622-8 2013 We inferred that curcumin was capable of impacting the IL-23/IL-17A axis by inhibiting IL-1beta/IL-6 and then indirectly down-regulating IL-17A/IL-22 production. Curcumin 17-25 interleukin 17A Mus musculus 137-143 27026486-8 2016 Moreover, Western blot analysis and immunostaining indicated that treatment with curcumin significantly reduced the expression of a vascular cell adhesion molecule-1 (VCAM-1), interferon-gamma (INF-gamma) and interleukin-17 (IL-17) in the mouse brain at 72h post-ICH. Curcumin 81-89 interleukin 17A Mus musculus 209-223 27026486-8 2016 Moreover, Western blot analysis and immunostaining indicated that treatment with curcumin significantly reduced the expression of a vascular cell adhesion molecule-1 (VCAM-1), interferon-gamma (INF-gamma) and interleukin-17 (IL-17) in the mouse brain at 72h post-ICH. Curcumin 81-89 interleukin 17A Mus musculus 225-230 23825622-4 2013 Here, we report that topical use of a curcumin gel formulation strongly inhibited imiquimod (IMQ)-induced psoriasis-like inflammation, the development of which was based on the IL-23/IL-17A axis. Curcumin 38-46 interleukin 17A Mus musculus 183-189 23825622-6 2013 Real-time PCR showed that mRNA levels of IL-17A, IL-17F, IL-22, IL-1beta, IL-6 and TNF-alpha cytokines were decreased significantly by curcumin in ear skin, an effect similar to that of clobetasol. Curcumin 135-143 interleukin 17A Mus musculus 41-47 23840617-3 2013 Treatment with curcumin attenuated alloreactive T cell proliferation and inhibited the production of interferon (IFN)-gamma and interleukin (IL)-17. Curcumin 15-23 interleukin 17A Mus musculus 128-147 22402368-5 2012 In this study, we show that C57BL/6 mice induced to develop EAE express elevated levels of interferon (IFN) gamma and interleukin (IL)-17 in the central nervous system (CNS) and lymphoid organs that decreased significantly following in vivo treatment with curcumin. Curcumin 256-264 interleukin 17A Mus musculus 118-137 34198046-0 2021 Comparative protein profiling reveals the inhibitory role of curcumin on IL-17A mediated minichromosome maintenance (MCM) proteins as novel putative markers for acute lung injury in vivo. Curcumin 61-69 interleukin 17A Mus musculus 73-79 34198046-7 2021 Several trends were identified from the proteomic subset which revealed that IL-17A induces expressions of proteins like MCM2, MCM3, and MCM6 along with other proteins involved in DR. Interestingly, curcumin was found in suppressing the expression levels of these proteins. Curcumin 199-207 interleukin 17A Mus musculus 77-83 35609329-10 2022 Moreover, curcumin suppressed the inflammatory response by reducing TNF-alpha, IL-6, and IL-17 secretion in CIA-stimulated mice. Curcumin 10-18 interleukin 17A Mus musculus 89-94 35609329-11 2022 Curcumin has an excellent anti-RA effect in vivo and in vitro, which is exerted by inhibiting the expression of pro-inflammatory factors TNF-a, IL-6 and IL-17 and inhibiting the activation of PI3K/AKT signaling pathway. Curcumin 0-8 interleukin 17A Mus musculus 153-158 32535538-0 2020 Effect of curcumin on IL-17A mediated pulmonary AMPK kinase/cyclooxygenase-2 expressions via activation of NFkappaB in bleomycin-induced acute lung injury in vivo. Curcumin 10-18 interleukin 17A Mus musculus 22-28 32535666-6 2020 Compared with the CLP group, the increased IL-35 expression in CLP with the curcumin pretreatment (CLP + Cur) group was consistent with the decreased severity of lung injury, IL-17A protein levels in lung tissue, and Treg-related cytokines levels. Curcumin 76-84 interleukin 17A Mus musculus 175-181 33179078-9 2021 IL-10 level in the colon was significantly increased, while inflammatory cytokines IL-6, IL-17 and IL-23 were significantly reduced following curcumin treatment. Curcumin 142-150 interleukin 17A Mus musculus 89-94 32618472-12 2020 Therapeutic efficacy of curcumin exhibited a protective role against the progression of pulmonary fibrosis, which promises the potent therapeutic modality to target IL-17A mediated p53-fibrinolytic system during pulmonary fibrosis. Curcumin 24-32 interleukin 17A Mus musculus 165-171 32535538-5 2020 Curcumin could also suppress the expressions of NF-kappaB-p105 in BLM/IL-17A exposed mice. Curcumin 0-8 interleukin 17A Mus musculus 70-76 32534511-8 2020 The levels of IL-6, IL-17, and IFN-gamma, as well as FBS, was significantly decreased in the treated group with curcumin compared to the diabetic group mice (p<0.05). Curcumin 112-120 interleukin 17A Mus musculus 20-25 32572733-0 2020 Curcumin attenuates IL-17A mediated pulmonary SMAD dependent and non-dependent mechanism during acute lung injury in vivo. Curcumin 0-8 interleukin 17A Mus musculus 20-26 32572733-4 2020 C57BL/6 mice were exposed to IL-17A and curcumin was administered as an intervention to modulate the IL-17A-induced alveolar damage. Curcumin 40-48 interleukin 17A Mus musculus 101-107 32572733-7 2020 Curcumin intervention in vivo promoted the resolution of IL-17A-induced ALI and attenuated pulmonary damage. Curcumin 0-8 interleukin 17A Mus musculus 57-63 32572733-11 2020 Our study indicates that IL-17A participates in the development of ALI in both SMAD dependent and independent manner and the IL-17A signaling components were effectively controlled by curcumin, suggesting probable anti-inflammatory use of curcumin during ALI. Curcumin 184-192 interleukin 17A Mus musculus 125-131 32572733-11 2020 Our study indicates that IL-17A participates in the development of ALI in both SMAD dependent and independent manner and the IL-17A signaling components were effectively controlled by curcumin, suggesting probable anti-inflammatory use of curcumin during ALI. Curcumin 239-247 interleukin 17A Mus musculus 125-131 32004976-13 2020 IL-17A, MPO-producing neutrophils, and NF-kappaB p65 expression in lungs of CLP mice decreased significantly after pretreatment with curcumin. Curcumin 133-141 interleukin 17A Mus musculus 0-6 32006622-6 2020 The anti-psoriatic efficacy of Cur-GA-silica was confirmed by Psoriasis Area and Severity Index (PASI) evaluation, histological evaluation and decreased IL-17A in the imiquimod-induced psoriasiform mouse skin analyzed by enzyme-linked immunosorbent assay. Curcumin 31-34 interleukin 17A Mus musculus 153-159